All of the work published to date on supervoltage roentgen therapy indicates a lack of specific cancericidal advantage in relation to wave length of the radiation. The chief advantage of super-voltage therapy is an increase in quantity of radiation delivered to a deeply situated tumor. Normal tissues unavoidably irradiated have shown some rather slight arbitrary differences in tolerance to higher-energy radiations. These differences may well be related to difficulties in physical dosage measurements of absorption of qualities so closely related as those produced at 200,000 volts, 400,000 volts, and 1,000,000 volts. The 23,000,000-volt betatron has given us an opportunity to evaluate differences in dosage effects over a much greater range of voltage than hitherto available. The purpose of this presentation is to compare the dosage distribution of x-rays from a 400,000-volt x-ray machine with those from a 23,000,000-volt betatron. There are a minimum of five differences in the absorption of the radiations from these two sources which should be emphasized at the start. These are as follows: 1. The maximum dose for 400-kv. x-rays with a half-value layer of 2.75 mm. Cu is approximately at the surface, while with the betatron it is slightly over 4 cm. within the body (1, 4). 2. The relative dose for 400-kv. x-rays is 37 per cent at 10 cm. and 10 per cent at 20 cm.; with the betatron it is 81 per cent at 10 cm. and 54 per cent at 20 cm., both with 10-cm. ports (1,4). 3. Side scatter is important for 400-kv.p. x-rays, but for the betatron x-rays scatter is predominantly forward (1,4). 4. The entrance skin dose is at the peak with 400-kv. x-rays and at approximately 35 per cent of the peak dose with the betatron. The exit skin dose is usually negligible with 400-kv. x-rays, while with the betatron it may be higher than the entrance skin dose (1). 5. Relative absorption of the radiations is high in bone and low in fat at lower voltages; it is more nearly equal with the betatron (3, 6). For practical purposes we have selected 5 patients treated with the betatron and have compared their actual dose distributions with those which might have resulted from the use of the lower-energy machine. These patients had tumors located in different parts of the body and in both central and eccentric position. Treatment planning was conducted in a routine fashion and without thought or reference to competing methods, with the exception of one chest case for purposes of demonstration. The number of fields of treatment differ with the two technics, simply because the 23-mev x-rays have so much greater range that one has an almost unlimited number of approaches to a lesion. The number of treatments, size of daily treatments, rate of dosage administration, and over-all treatment period in terms of weeks are not significantly different between the two methods.
Read full abstract